Media Summary: The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker What is the significance of intellectual property to life science companies? What do most of the public not understand about ...

Eli Lilly Ceo On 3q - Detailed Analysis & Overview

The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker What is the significance of intellectual property to life science companies? What do most of the public not understand about ...

Photo Gallery

Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic
Eli Lilly CEO on 3Q Results, Drug-Pricing Reforms
Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
Eli Lilly CEO: Our pill supply can 'reach the planet'
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipeline
Eli Lilly’s CEO David Ricks delves into the drivers of the healthcare industry
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
View Detailed Profile
Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic

Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic

Eli Lilly CEO

Eli Lilly CEO on 3Q Results, Drug-Pricing Reforms

Eli Lilly CEO on 3Q Results, Drug-Pricing Reforms

Oct.23 -- Dave Ricks, chief

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Eli Lilly

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly

Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Dave Ricks, the

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

CNBC's Angelica Peebles and

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

(0:00) Introducing

Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipeline

Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipeline

Eli Lilly CEO

Eli Lilly’s CEO David Ricks delves into the drivers of the healthcare industry

Eli Lilly’s CEO David Ricks delves into the drivers of the healthcare industry

What is the significance of intellectual property to life science companies? What do most of the public not understand about ...

Eli Lilly CEO on Fighting Obesity, Developing New Drugs

Eli Lilly CEO on Fighting Obesity, Developing New Drugs

Eli Lilly

Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results

Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results

CNBC's Angelica Peebles and